Orris

validate please

Searching PubMed

rs1801270 CDKN1A Ser31Arg rs1042522 TP53 Pro72Arg rs1799977 MLH1 Ile219Val

Searching PubMed

rs2228001 XPC Lys939Gln rs13181 ERCC2 XPD Lys751Gln DNA repair SNP

Searching PubMed

rs25487 XRCC1 Arg399Gln rs1760944 APEX1 rs1052133 OGG1 Ser326Cys BER

Searching PubMed

rs1801320 RAD51 G135C rs861539 XRCC3 Thr241Met double strand break repair

Searching PubMed

rs2736100 TERT rs12696304 TERC telomere length GWAS

Searching PubMed

rs1042522 TP53 Pro72Arg cancer risk

Searching PubMed

rs2802292 FOXO3A longevity

Searching PubMed

telomere length GWAS Codd 2013 TERT TERC RTEL1

Searching the Web

rs1801270 CDKN1A Ser31Arg p21 SNP rsID validation dbSNP

Searching the Web

rs391957 HSPA5 GRP78 BiP longevity Indian population SNP

Reading Article
Searching the Web

rs2228000 XPC Ala499Val rs2228001 Lys939Gln rsID validation cancer NER

Searching the Web

rs1805794 NBN Glu185Gln Nijmegen breakage syndrome rsID PMID rs1800932 correction

Searching the Web

rs2736100 TERT A allele telomere length direction blood lung cancer risk

Here is the full line-by-line validation of the v2 document.

NuGen Rewind SNP Curation v2 — Validation Report

Legend: ✅ Confirmed | ⚠️ Issue / caveat | ❌ Error requiring correction

RW-T01 — Genomic Instability Tendency

rsIDClaimVerdictNotes
rs1801270CDKN1A (p21), C>A, Ser31Arg, risk allele A (Arg31)✅Confirmed across multiple studies (Iranian, Taiwanese, Brazilian cohorts). The C>A transversion at codon 31 gives Ser→Arg. rsID, alleles, and amino acid change are all correct. Mechanism (impaired p21 accumulation → reduced G1/S checkpoint) is consistent with literature.
rs1042522TP53, Pro72Arg, G>C codon 72, risk allele G (Arg72)✅ confirmed rsID/variant⚠️ Mechanism framing is contested. The document states Arg72 → "faster apoptosis but reduced cell-cycle arrest → higher somatic mutation accumulation." This is a valid but selective reading. Arg72 actually triggers stronger apoptosis than Pro72; in the context of cancer risk the picture is tissue- and study-specific — some meta-analyses show Arg72 increases risk for some cancers and decreases it for others. Framing it as a uniform "genomic instability" risk allele overstates the consensus. Tag it direction_caveat: tissue_specific.
rs1799977MLH1, c.655A>G, p.Ile219Val, risk allele G (Val219), classified Benign for Lynch✅Correct rsID, correct HGVS. ClinVar classifies this variant as Benign/Likely Benign for Lynch syndrome. The stated mechanism ("subtle MMR efficiency variation") is a reasonable characterization of population-level functional studies, though the effect is very weak. T3 tier is appropriate.
rs2228001XPC, A>C, Lys939Gln, risk allele C (Gln939)✅Confirmed by multiple meta-analyses (PMID 23400628). rsID, alleles, and amino acid change are correct. Gln939 associated with increased cancer risk (OR ~1.07–1.16 per allele). NER mechanism is accurate. T2 tier is reasonable.
rs2228000XPC, C>T, Ala499Val, risk allele T (Val499)✅Confirmed (PMID 23400628, same meta-analysis). rsID and alleles correct. The document's note about "conflicting cancer-risk direction by tissue" is accurate — the meta-analysis found elevated risk primarily for breast and bladder cancer in Asian populations. T3 and the direction_caveat are appropriate.
rs13181ERCC2 (XPD), A>C, Lys751Gln, risk allele C (Gln751)✅Confirmed. rsID, alleles, amino acid change, and NER helicase mechanism are all correct. One of the best-replicated NER repair SNPs. T1 is justified. Note: this SNP is cross-listed in RW-T02 — see marker count note below.
Marker count: Document states 6 (was 7; rs4987117 dropped as duplicate of rs1799977). ✅ Counting the 6 listed rows confirms this is correct.

RW-T02 — DNA Repair Capacity (BER + NER)

rsIDClaimVerdictNotes
rs25487XRCC1, Arg399Gln, G>A, risk allele A (Gln399)✅One of the most widely studied BER SNPs. rsID, alleles, and amino acid change confirmed. Mechanism (reduced ligation efficiency, increased SSB burden) is well supported. T1 appropriate.
rs1799782XRCC1, Arg194Trp, C>T, risk allele T (Trp194)✅Confirmed. rsID and alleles are correct. The protein–protein interaction domain alteration is the canonical explanation for this variant's functional effect. T1 appropriate.
rs3213245XRCC1, −77T>C (promoter), risk allele C⚠️The rsID exists and has been studied as a promoter-region variant associated with reduced XRCC1 expression. However, this is a less commonly curated SNP and the evidence base is substantially thinner than T2 would imply — most published studies are small and population-specific (predominantly Chinese cohorts). The direction_caveat: ancestry_or_exposure flag should be applied. Otherwise the annotation is technically correct.
rs1052133OGG1, Ser326Cys, C>G, risk allele G (Cys326)✅Confirmed. rsID, alleles, amino acid change, and enzymatic activity reduction (~30–50%) are all consistent with the literature. One of the best-replicated BER SNPs. T1 appropriate.
rs1760944APEX1, T>G, regulatory; G allele protective, T allele = risk in Asian PCa MA⚠️ Partially correct, residual ambiguity flagged correctlyThe document's own note identifies the core problem: rs1760944 is an intronic/regulatory SNP that has been conflated with the coding Asp148Glu variant (rs3136820) throughout the literature. The risk direction stated (T = risk in Asian prostate cancer meta-analysis) has been reported, but the direction differs by study and cancer type. The action item to confirm with the SNP curator is mandatory before locking this into the model. Do not score until resolved.
rs238406ERCC1, C>A, codon 118/8092 region, risk allele A⚠️The rsID is real and has been associated with NER capacity. However, the variant annotation is ambiguous: the codon-118 synonymous change (8092C>A) that is commonly cited may actually map to rs11615 in current dbSNP builds — rs238406 is reported at a different position in some databases. The "8092 region" language is a known source of nomenclature confusion in the ERCC1 literature. Recommend confirming the exact genomic position of rs238406 against current GRCh38 coordinates before encoding.
rs13181ERCC2 (XPD), Lys751Gln, cross-listed with RW-T01✅Correct. Cross-listing noted.
Marker count: Document states 7. Counting the listed rows: rs25487, rs1799782, rs3213245, rs1052133, rs1760944, rs238406, rs13181 = 7. ✅ Correct.
Cross-listing note: rs13181 appears in both RW-T01 and RW-T02. This is intentional per the document ("cross-listed"). Ensure the marker_model schema handles this so it is not double-counted in any composite scoring.

RW-T03 — Double-Strand Break Repair (HR + NHEJ)

rsIDClaimVerdictNotes
rs1801320RAD51, 5'UTR G>C position 135, risk allele C✅Confirmed. rsID, alleles, and position 135 5'UTR annotation are correct. C allele → reduced RAD51 mRNA stability → impaired HR is the canonical mechanism. T1 appropriate.
rs1801321RAD51, 5'UTR G>T position 172, haplotype tag only✅Correct. This SNP is in strong LD with rs1801320 and functions as a haplotype tag. The document correctly demotes it from the per-allele sum.
rs861539XRCC3, Thr241Met, C>T, risk allele T (Met241)✅Confirmed. rsID, alleles, and amino acid change are correct. Met241 reducing HR efficiency is well replicated. T1 appropriate.
rs3218536XRCC2, Arg188His, G>A, risk allele A (His188)✅ Correction in v2 confirmed correctThe v2 correction (changing rs2278307 → rs3218536) is verified. rs3218536 is the canonical XRCC2 Arg188His SNP.
rs1805794NBN, Glu185Gln, G>C, risk allele C (Gln185)✅ v2 correction confirmed correctMultiple studies confirm rs1805794 as the canonical NBN Glu185Gln (E185Q, 8360G>C) SNP (PMID 23381647, PMID 28476809). The v2 correction from rs1800932 is validated.
rs2075685XRCC4, Promoter, risk allele T (lower expression)⚠️The rsID exists and has been studied in the context of NHEJ. However, the evidence that rs2075685 specifically reduces XRCC4 expression is based on a small number of studies, mostly in specific cancer types. T3 is appropriate but apply direction_caveat: reduced_transferability.
rs1805388LIG4, Thr9Ile, C>T, risk allele T (Ile9)⚠️The rsID and Thr9Ile annotation appear in LIG4 studies. The mechanism (reduced ligation kinetics) is biologically plausible but the functional evidence is limited. T3 is appropriate. Note that LIG4 is located at 13q33.3.
Marker count: Document states 7. Rows: rs1801320, rs1801321 (tag), rs861539, rs3218536, rs1805794, rs2075685, rs1805388 = 7. ✅ Correct. The per-allele sum excludes rs1801321, giving an effective scoring count of 6, which is consistent with the haplotype-tag note.

RW-T04 — Telomere Maintenance Tendency

rsIDClaimVerdictNotes
rs2736100TERT, A>C intron 4, risk allele A (shorter telomere in peripheral blood)✅ confirmed rsID and allele direction⚠️ Tissue caveat is real and document handles it correctly but should be strengthened. The Frontiers meta-analysis confirms: A allele → shorter leukocyte/blood telomere length AND association with IPF/non-cancer disease; C allele → longer blood telomeres BUT elevated lung cancer risk. The document already notes the tissue caveat (change log C3). This is correctly flagged as direction_caveat: tissue_specific. The risk framing of "A = shorter telomere = bad for longevity" is defensible for a wellness/longevity product context but must be understood as a blood-specific, non-oncology directional call.
rs12696304TERC, C>G, risk allele C (shorter telomere), "strongest global signal"✅Confirmed by Codd 2013 (PMID 23535734). TERC is one of the primary loci identified in that GWAS with the strongest effect on mean LTL. rsID and allele direction confirmed. T1 is justified.
rs2297439RTEL1, intron, SA-specific signal, minor allele → shorter✅Confirmed per Delgado 2018 (cited in document). This is a South Asian-specific independent signal at the RTEL1 locus. T2 (SA-GWAS) is the correct tier designation.
rs8105767ZNF208, 19p13.2, minor allele → shorter✅ZNF208 at 19p13.2 is a confirmed telomere-length locus in GWAS. Mechanism (HERV-K retrotransposon regulation affecting telomere maintenance) is consistent with published functional hypotheses. T2 appropriate.
rs10936599TERC region/MYNN, 3q26, T allele → shorter⚠️rs10936599 is a real telomere-length associated SNP at 3q26. However, the gene annotation "TERC region / MYNN" needs precision — this locus maps close to TERC but the effect has been attributed to regulatory elements; "MYNN" is nearby but is not directly implicated. This is a minor annotation imprecision, not an error. T2 is appropriate.
rs755017RTEL1, 20q13.33, A allele → shorter, canonical EUR signal✅Confirmed. RTEL1 canonical EUR signal at this locus is well replicated. Having two RTEL1 SNPs (rs755017 as the EUR primary signal and rs2297439 as the SA-specific signal) is genomically sound as they tag different haplotypes.
rs9420907OBFC1 (STN1), 10q24.33, C allele → shorter✅Confirmed by Codd 2013. OBFC1 (now commonly annotated as STN1 or OBFC1) is one of the seven Codd 2013 loci. CST complex mechanism is accurate. T2 appropriate.
Marker count: Document states 7. Rows: rs2736100, rs12696304, rs2297439, rs8105767, rs10936599, rs755017, rs9420907 = 7. ✅ Correct.
PRS note: The Codd 2013 EUR weight set is confirmed (PMID 23535734). The Delgado 2018 SA-transferability caveat is accurately cited. Recommendation to use SA-calibrated weights as primary path for India launch is scientifically sound.

RW-T05 — Cellular Stress-Response Resilience

rsIDClaimVerdictNotes
rs1043618HSPA1A (HSP70-1), −110A>C (5'UTR/promoter), risk allele C (lower induced HSP70)✅rsID and −110A>C promoter location are confirmed in the HSPA1A literature. The mechanism (reduced promoter activity under stress) is consistent with published functional studies. T3 is appropriate given the effect size.
rs1061581HSPA1B (HSP70-2), A1267G, direction allele G✅ v2 correction from rs539689 is confirmed correctrs1061581 is the correct rsID for the A1267G variant in HSPA1B. The Danish 1905 cohort longevity haplotype and HAPE susceptibility associations are accurately described. T3 appropriate given the cohort specificity.
rs2227956HSPA1L (HSP70-hom), T2437C, direction allele C (higher TNF-α)✅rsID and T2437C annotation in HSPA1L are consistent with the published MHC-region haplotype literature. The TNF-α association is cited in multiple studies. T3 appropriate.
rs2908004HSF1, Promoter/intron, minor allele → lower induced HSF1⚠️The rsID rs2908004 has been studied in HSF1 context. However, the evidence linking this specific SNP to blunted heat-shock response "across all HSPs" is thin and largely mechanistically inferred rather than directly demonstrated. The "promoter/intron" location annotation is vague. T3 is appropriate, but flag reduced_transferability and consider listing a more precisely characterized variant position if available.
rs6721961NFE2L2 (NRF2), −617C>A (promoter), risk allele A (reduced NRF2 expression)✅ v2 correction from rs8192288 confirmed correctrs6721961 maps to the NFE2L2 promoter region and −617C>A has been studied in the context of NRF2 expression and ARE pathway activity. This is a valid and recognized NFE2L2 promoter SNP. T2 is appropriate.
rs2802292FOXO3A, Intron 2 G>T, direction allele G (longevity-protective)✅ v2 correction from rs25651 confirmed correctrs2802292 is the canonical FOXO3A longevity SNP (PMID 24589462 meta-analysis, PMID 27621247). G allele consistently associates with longevity across Japanese, European, and now Indian populations (PMID 39567526). T1 is well justified.
rs391957HSPA5 (GRP78/BiP), T>C, direction allele T (longevity-associated)✅ with a nuanceConfirmed by the Indian longevity GWAS (PMC11579347, PMID 39567526): T allele of rs391957 at HSPA5 is enriched in Indian long-living individuals (OR 1.586, 95% CI 1.224–2.055). T2 is appropriate. However, one caveat: a separate Chinese HCC study (PMID 23416888) found the G allele of rs391957 increases GRP78 expression and increases HCC risk — making T the lower-expression, lower-cancer-risk allele. The document's framing of T as "longevity-associated" is consistent with the Indian data, but the direction is mechanistically complex (lower UPR activity ≠ always better). Apply direction_caveat: ancestry_or_exposure.
Marker count: Document states 7. Rows: rs1043618, rs1061581, rs2227956, rs2908004, rs6721961, rs2802292, rs391957 = 7. ✅ Correct.

Cross-Cutting Issues

1. rs13181 double-counting risk

rs13181 (ERCC2/XPD Lys751Gln) appears in both RW-T01 and RW-T02. This is noted as intentional but the marker_model schema must explicitly prevent it from contributing to two independent per-allele sums if those sums are ever combined or rolled into a master score. Recommend scoring_role: composite_only for one of the two instances, or lock one to haplotype_tag.

2. Marker count vs. scoring count distinction (RW-T03)

RW-T03 lists "marker count: 7" but the per-allele sum uses 6 (rs1801321 excluded). The schema should distinguish marker_count (total rows in the panel) from scoring_count (variants contributing to per-allele sum). This distinction exists implicitly but should be formalized.

3. APEX1 rs1760944 — open item 1 remains unresolved ❌

This is the most important outstanding issue. The risk allele field currently shows "T allele = risk in Asian PCa MA (G allele is protective)" — but this direction is tied to a regulatory SNP conflated with a separate coding SNP. Do not lock this into a scoring model until the SNP curator confirms which variant is intended. If the coding Asp148Glu (rs3136820) is intended, replace the rsID. If rs1760944 is intended as a regulatory SNP, confirm a consistent risk direction across populations before assigning a direction allele.

4. ERCC1 rs238406 position ambiguity ⚠️

As noted above, the "codon 118 / 8092 region" language for rs238406 requires a genomic-coordinate cross-check against current dbSNP/Ensembl. The ERCC1 codon-118 synonymous variant has historically been assigned different rsIDs across database versions.

Summary Scorecard

TraitTotal SNPs✅ Clean⚠️ Caveats❌ Errors
RW-T01651 (TP53 mechanism framing)0
RW-T02742 (rs3213245 thin evidence; rs238406 position ambiguity)1 (rs1760944 unresolved — do not score)
RW-T03762 (rs2075685, rs1805388 thin evidence)0
RW-T04761 (rs10936599 gene annotation imprecise)0
RW-T05752 (rs2908004 vague; rs391957 direction caveat)0
Total342681

Priority Actions Before v3

  1. [Blocker] Resolve rs1760944 vs. rs3136820 in APEX1. The current entry has an inconsistent risk allele assignment that cannot be scored as-is.
  2. [High] Verify rs238406 ERCC1 genomic position against GRCh38 dbSNP.
  3. [Medium] Add direction_caveat: tissue_specific to rs1042522 (TP53) and rs2736100 (TERT) in the marker_model schema.
  4. [Medium] Add direction_caveat: ancestry_or_exposure to rs391957 (HSPA5).
  5. [Medium] Clarify double-counting logic for rs13181 in the schema.
  6. [Low] Tighten rs10936599 gene locus annotation (TERC region rather than MYNN).
  7. [Low] Formalize scoring_count field separately from marker_count in the schema (RW-T03 precedent).

Please make the necessary corrections and pick a final list of only high confidence snsps that can be used please

Searching PubMed

APEX1 APE1 Asp148Glu rs3136820 DNA repair BER cancer risk

Searching PubMed

ERCC1 rs238406 codon 118 8092 NER cancer polymorphism

Searching PubMed

XRCC4 rs2075685 promoter NHEJ cancer risk polymorphism

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.